HealthEquity (HQY)
(Delayed Data from NSDQ)
$81.63 USD
+1.91 (2.40%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $81.67 +0.04 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
HQY 81.63 +1.91(2.40%)
Will HQY be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for HQY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HQY
HealthEquity (HQY) Q4 Earnings Surpass Estimates, Margins Up
Compared to Estimates, HealthEquity (HQY) Q4 Earnings: A Look at Key Metrics
HQY: What are Zacks experts saying now?
Zacks Private Portfolio Services
HealthEquity (HQY) Beats Q4 Earnings and Revenue Estimates
Here's Why You Should Retain HealthEquity (HQY) Stock Now
Here's Why HealthEquity (HQY) is a Strong Momentum Stock
Other News for HQY
HealthEquity price target raised by $16 at Jefferies, here's why
Jefferies Keeps Their Buy Rating on Healthequity (HQY)
Director Evelyn Dilsaver Sells 32,500 Shares of HealthEquity Inc (HQY)
Buy Rating on Healthequity (HQY) Affirmed Amid HSA Market Growth and Competitive Outperformance
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Aerovate Therapeutics (AVTE) and Delcath Systems (DCTH)